Online inquiry

IVTScrip™ mRNA-Anti-CD276, MG-A271(Cap 0, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ11567MR)

This product GTTS-WQ11567MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD276 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001024736.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 80381
UniProt ID Q5ZPR3
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD276, MG-A271(Cap 0, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ11567MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9900MR IVTScrip™ mRNA-Anti-CSF2, KB-003(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA KB-003
GTTS-WQ9298MR IVTScrip™ mRNA-Anti-TACSTD2, IMMU-132(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA IMMU-132
GTTS-WQ12680MR IVTScrip™ mRNA-Anti-FZD1&FZD2&FZD5&FZD7&FZD8, OMP-18R5(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA OMP-18R5
GTTS-WQ10940MR IVTScrip™ mRNA-Anti-HAVCR2, MBG-453(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MBG-453
GTTS-WQ12671MR IVTScrip™ mRNA-Anti-FZD1&FZD2&FZD5&FZD7&FZD8, OMP-18R5(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA OMP-18R5
GTTS-WQ6075MR IVTScrip™ mRNA-Anti-CCL2, CNTO 888(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA CNTO 888
GTTS-WQ15527MR IVTScrip™ mRNA-Anti-TGM2, UCB-7858(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA UCB-7858
GTTS-WQ3704MR IVTScrip™ mRNA-Anti-MSLN, BAY 2287409(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BAY 2287409
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW